Extended Data Fig. 7: Adoptively transferred CTLs with Rgs1 knockdown reveals enhanced anti-tumor effects in mouse breast and lung cancer models.
a,b, Mice bearing MMTV-PyMT tumors and LLC1 tumor grafts were intravenously injected with the tumor-specific CTLs transduced with shRgs1-1, shRgs1-2, shGFP or shvec and labeled with CFSE (green). a, The tumor grafts were imaged 2 days after T-cell transfusion by intravital two-photon microscopy. The blood vessels were indicated by i.v. injection of Rhodamine-dextrane (red) (n = 6 per group). Scale bar, 100 μm. b, MMTV-PyMT tumors and LLC1 tumor grafts infiltrating CTLs were isolated 7 days after T cell transfusion and analyzed by flow cytometry. Bars correlate to the percentages of gated CD8+ cells stained for CFSE, CD44, CD69, perforin, granzyme B or IFN-γ (mean±s.d.; n = 5 per group). MMTV-PyMT tumor: CFSE: *P = 0.0124 (shvec). IFN-γ: *** P = 0.0003 (shRgs1-1), ** P = 0.0017 (shRgs1-2). Perforin: *** P = 0.0002 (shRgs1-2). ****P < 0.001 compared with tumors without CTLs transfusion. #### P < 0.0001 compared with tumors receiving shvec-transduced CTL transfusion. LLC: CD44: ***P = 0.0006 (shRgs1-2). CD69: ** P = 0.0012 (shRgs1-2). Perforin: ** P = 0.0026 (shRgs1-1). ****P < 0.001 compared with tumors without CTLs transfusion. ####P < 0.0001 compared with tumors receiving shvec-transduced CTL transfusion. c, Quantification of Fig. 5d (mean±s.d.; n = 6 per group). %ID/g, the percentage of injected dose per gram of tissue. ****P < 0.0001. P values were determined by two-tailed one-way ANOVA with Dunnett’s multiple comparison test (b, c).
